Abstract:Introduction: The major challenge to effective oncolytic viral-mediated cancer therapy is the lack of tumor-specific targeting. Myeloid derived suppressor cells (MDSCs) are immature myeloid cells induced by tumor factors which have been shown to migrate to tumors. Better understanding of the kinetics of MDSC migration may enable the use of MDSCs as delivery vectors for tumor-specific therapies. Vesicular Stomatitis Virus (VSV) is an oncolytic rhabdovirus which requires high doses for effective peripherally administered cancer therapy. These doses carry a likelihood of neurotoxic effects in humans. We hypothesize that MDSCs can improve delivery and decrease side effects of VSV therapy. Methods: Ly6C+ monocytic MDSCs were isolated from tumor-bearing BALB/c mice. Cells were stained with Feridex and PKH26 dye and adoptively transferred into BALB/c mice with intrahepatic MCA26 colon cancer. Mice received daily MRI and were sacrificed for FACS, relaxometry, or mass spectrometry. Intrahepatic MCA26 tumor-breaing mice were treated with injection of 5x106 MDSCs cultured with VSV or VSV(M3) virus (MOI:300), with or without α-VSV-G ab and compared for survival to mice receiving PBS, MDSCs alone, free virus, and Ly6c- cells cultured with VSV. Mice were sacrificed and organs harvested for histology and TCID50. Results: We demonstrate via MRI that MDSCs migrate to tumors in an adoptive transfer model of murine hepatic metastases of colon cancer. MDSC levels peak intratumorally 72 hrs after transfer and are identified peripherally and perivasciularly. Intratumoral MDSC levels are elevated compared to spleen (38±2%Injected Dose (%ID) vs 13±0.6%ID, 72hrs, p<0.001), and liver (0.5±1%ID, p<0.001) via mass spectrometry and relaxometry. This is confirmed by FACS, which shows a 7-fold increase of MDSC signaling in the tumor compared to background (p=0.001). We then employ MDSCs as a delivery vehicle for VSV. VSV-infected MDSCs significantly prolong survival in mice with hepatic colon cancer over systemic administration of VSV alone (29.8 days vs 24 days; p<0.0002). Furthermore, the improvement of VSV binding efficiency on MDSCs leads to significantly improved survival when VSV is conjugated to MDSCs using α-VSV-G ab (52.9 days vs 24.9 days; p<0.0001) demonstrating 26% overall survival and no significant toxicity. We confirm increased viral delivery to tumors and decreased delivery to other tissues through histology and TCID50, indicating an improved therapeutic index for VSV therapy when administered via MDSCs. Conclusions: This study demonstrates a proof-of-principle for MDSCs preferentially targeting therapeutics to metastatic tumors. in the future we anticipate that this technique may be applied to a variety of targeted tumor therapies.

Inhibition of Tumor-Induced Myeloid-Derived Suppressor Cell Function by a Nanoparticulated Adjuvant

VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients

A Novel Role for Myeloid Derived Suppressor Cells in Tumor-specific Therapeutic Targeting

Immune Adjuvant Targeting Micelles Allow Efficient Dendritic Cell Migration to Lymph Nodes for Enhanced Cellular Immunity.

Self-Assembled, Adjuvant/Antigen-Based Nanovaccine Mediates Anti-Tumor Immune Response against Melanoma Tumor

Dectin-1 Activation Subverts the Suppression of Myeloid-Derived Suppressor Cells by Inducing PMN-MDSC Apoptosis and Monocytic MDSC Differentiation to Potent Antigen-Presenting Cells in Cancer (TUM6P.961)

A Versatile Supramolecular Nanoadjuvant That Activates NF-κB for Cancer Immunotherapy

A promising self-nanoemulsifying adjuvant with plant-derived saponin D boosts immune response and exerts an anti-tumor effect

Self-adjuvant Astragalus polysaccharide-based nanovaccines for enhanced tumor immunotherapy: a novel delivery system candidate for tumor vaccines

Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity

Pseudoneutrophil Cytokine Sponges Disrupt Myeloid Expansion and Tumor Trafficking to Improve Cancer Immunotherapy.

Self-assembly Nanovaccine Containing TLR7/8 Agonist and STAT3 Inhibitor Enhances Tumor Immunotherapy by Augmenting Tumor-Specific Immune Response.

Intratumoral Delivery of M-CSF by Calcium Crosslinked Polymer Micelles Enhances Cancer Immunotherapy

Dual-responsive PEG-lipid Polyester Nanoparticles for Sirna and Vaccine Delivery Elicit Anti-Cancer Immune Responses by Modulating Tumor Microenvironment

Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment

Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment

Optimized Fabrication of Dendritic Mesoporous Silica Nanoparticles as Efficient Delivery System for Cancer Immunotherapy

High Cellular Internalization of Virus-Like Mesoporous Silica Nanoparticles Enhances Adaptive Antigen-Specific Immune Responses against Cancer

Anticancer Vaccination with Immunogenic Micelles That Capture and Release Pristine CD8+ T-Cell Epitopes and Adjuvants

Nanomedicines modulating myeloid-derived suppressor cells for improving cancer immunotherapy

Synergistic anti-tumor efficacy of a hollow mesoporous silica-based cancer vaccine and an immune checkpoint inhibitor at the local site